alimemazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2749 84-96-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alimemazine
  • alimemazine tartrate
  • temaril
  • trimeprazine tartrate
  • trimeprazine
  • alimezine
  • methylpromazine
  • teralene
A phenothiazine derivative that is used as an antipruritic.
  • Molecular weight: 298.45
  • Formula: C18H22N2S
  • CLOGP: 5
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.55
  • ROTB: 4
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
30 mg P

ADMET properties:

PropertyValueReference
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.980 Moderate 0.74
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.388 Moderate 0.74
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 29.512 10^-6 cm/s Moderate 0.74
dh-clint Dog hepatocyte intrinsic clearance 79.250 uL/min/10^6 cells Moderate 0.74
dppb Dog plasma protein binding (% unbound) 3.500 % Moderate 0.74
fcs-ppb Fetal calf serum protein binding (% unbound) 10.800 % Moderate 0.74
herg hERG pIC50 5.974 pIC50 Moderate 0.74
hh-clint Human hepatocyte intrinsic clearance 11.885 uL/min/10^6 cells Moderate 0.74
hlm-clint Human liver microsomal intrinsic clearance 31.769 uL/min/mg protein Moderate 0.74
hppb Human plasma protein binding (% unbound) 5.050 % Moderate 0.74
kinase-safety-class ACVR2B,AKT2,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK5,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK12,MET,NTRK2,PDK2,PDK4,PDPK1,PIM2,PRKDC,TEK 26
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.437 Moderate 0.74
mh-clint Mouse hepatocyte intrinsic clearance 174.582 Moderate 0.74
mppb Mouse plasma protein binding (% unbound) 7.080 Moderate 0.74
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.355 Moderate 0.74
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.67
pppb Pig plasma protein binding (% unbound) 16.220 % Moderate 0.74
rh-clint Rat hepatocyte intrinsic clearance 220.800 uL/min/10^6 cells Moderate 0.74
rh-fuinc Rat hepatocyte fraction unbound in incubation 35.410 % Moderate 0.74
rppb Rat plasma protein binding (% unbound) 6.370 % Moderate 0.74
solubility-dd Solubility at pH 7.4 in DMSO 533.335 uM Moderate 0.74

Approvals:

DateAgencyCompanyOrphan
None FDA ALLERGAN HERBERT

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional overdose 1513.46 51.39 480 7161 93354 90527452
Intentional self-injury 1494.42 51.39 370 7271 28964 90591842
Coma 778.34 51.39 274 7367 72358 90548448
Poisoning deliberate 767.92 51.39 194 7447 16292 90604514
Somnolence 325.38 51.39 208 7433 208876 90411930
Toxicity to various agents 278.49 51.39 214 7427 287632 90333174
Suicide attempt 245.68 51.39 122 7519 75277 90545529
Tachycardia 218.32 51.39 146 7495 157527 90463279
Depressed level of consciousness 199.95 51.39 105 7536 72679 90548127
Bradypnoea 197.75 51.39 51 7590 4607 90616199
Electrocardiogram QT prolonged 191.87 51.39 102 7539 72354 90548452
Altered state of consciousness 145.69 51.39 65 7576 31467 90589339
Cardio-respiratory arrest 129.05 51.39 75 7566 63065 90557741
Substance use disorder 125.37 51.39 30 7611 1990 90618816
Rhabdomyolysis 121.23 51.39 67 7574 51189 90569617
Poisoning 120.07 51.39 46 7595 15171 90605635
Drug use disorder 118.40 51.39 39 7602 8304 90612502
Drug abuse 117.96 51.39 78 7563 82269 90538537
Hypotension 114.81 51.39 139 7502 325258 90295548
Hepatocellular injury 109.65 51.39 52 7589 28906 90591900
Hepatic cytolysis 109.42 51.39 53 7588 30863 90589943
Mydriasis 106.46 51.39 42 7599 14970 90605836
Hypothermia 101.50 51.39 41 7600 15534 90605272
Miosis 98.14 51.39 35 7606 9449 90611357
Akathisia 85.41 51.39 33 7608 11126 90609680
Drug reaction with eosinophilia and systemic symptoms 85.23 51.39 50 7591 42708 90578098
Bladder dilatation 83.76 51.39 19 7622 996 90619810
Drug dependence 76.71 51.39 41 7600 29286 90591520
Pneumonia aspiration 76.70 51.39 46 7595 40894 90579912
Cholestasis 76.46 51.39 44 7597 36255 90584551
Hyperthermia 66.62 51.39 27 7614 10308 90610498
Pyramidal tract syndrome 65.78 51.39 14 7627 545 90620261
Extrapyramidal disorder 63.92 51.39 30 7611 16273 90604533
Suicidal ideation 60.51 51.39 50 7591 73805 90547001
Serotonin syndrome 56.90 51.39 37 7604 37850 90582956
Hypercapnic coma 56.90 51.39 11 7630 262 90620544
Faecaloma 56.27 51.39 24 7617 10407 90610399
Asphyxia 54.33 51.39 21 7620 7082 90613724
Arthralgia 53.64 51.39 3 7638 778519 89842287
Pain 53.08 51.39 10 7631 996331 89624475

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 949.59 37.99 329 5320 53225 42562461
Poisoning deliberate 354.99 37.99 105 5544 10029 42605657
Intentional self-injury 258.46 37.99 91 5558 15111 42600575
Intentional overdose 255.45 37.99 128 5521 51328 42564358
Drug abuse 232.18 37.99 154 5495 104617 42511069
Miosis 192.83 37.99 71 5578 13375 42602311
Toxicity to various agents 179.97 37.99 184 5465 228952 42386734
Somnolence 172.11 37.99 145 5504 140960 42474726
Drug use disorder 168.47 37.99 60 5589 10273 42605413
Substance use disorder 163.76 37.99 50 5599 5295 42610391
Poisoning 130.92 37.99 55 5594 14644 42601042
Altered state of consciousness 81.90 37.99 50 5599 29209 42586477
Electrocardiogram QT prolonged 74.63 37.99 57 5592 47888 42567798
Pneumonia aspiration 74.60 37.99 58 5591 50020 42565666
Tachycardia 73.18 37.99 78 5571 101009 42514677
Extrapyramidal disorder 64.51 37.99 35 5614 16377 42599309
Depressed level of consciousness 63.82 37.99 52 5597 47918 42567768
Suicide attempt 61.39 37.99 50 5599 46050 42569636
Pulmonary oedema 57.07 37.99 51 5598 53221 42562465
Hepatocellular injury 52.64 37.99 35 5614 23643 42592043
Rhabdomyolysis 50.83 37.99 57 5592 77962 42537724
Cardio-respiratory arrest 47.31 37.99 48 5601 58588 42557098
Mydriasis 46.86 37.99 23 5626 8747 42606939
Intestinal obstruction 46.03 37.99 34 5615 27124 42588562
Drug ineffective 44.95 37.99 14 5635 630183 41985503
Faecaloma 44.48 37.99 20 5629 6250 42609436
Bradypnoea 44.37 37.99 18 5631 4375 42611311
Drug dependence 43.95 37.99 34 5615 29060 42586626
Tongue biting 41.23 37.99 12 5637 1075 42614611
Substance abuse 40.67 37.99 21 5628 8884 42606802
Catatonia 38.30 37.99 18 5631 6221 42609465

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 1696.75 37.68 595 11817 117274 110459613
Poisoning deliberate 1120.53 37.68 306 12106 26025 110550862
Intentional overdose 1082.95 37.68 443 11969 132058 110444829
Intentional self-injury 1061.76 37.68 317 12095 37112 110539775
Somnolence 502.80 37.68 347 12065 297102 110279785
Toxicity to various agents 442.12 37.68 391 12021 480164 110096723
Drug abuse 320.41 37.68 216 12196 177195 110399692
Miosis 295.50 37.68 106 12306 21877 110555010
Drug use disorder 288.30 37.68 99 12313 17975 110558912
Substance use disorder 287.69 37.68 80 12332 7210 110569677
Suicide attempt 261.81 37.68 156 12256 103238 110473649
Electrocardiogram QT prolonged 254.25 37.68 156 12256 108804 110468083
Tachycardia 253.75 37.68 207 12205 226438 110350449
Poisoning 245.79 37.68 100 12312 29005 110547882
Altered state of consciousness 222.93 37.68 115 12297 57511 110519376
Bradypnoea 217.85 37.68 67 12345 8582 110568305
Depressed level of consciousness 177.23 37.68 126 12286 112152 110464735
Rhabdomyolysis 162.65 37.68 123 12289 120278 110456609
Cardio-respiratory arrest 162.40 37.68 121 12291 115715 110461172
Pneumonia aspiration 158.64 37.68 104 12308 81129 110495758
Hepatocellular injury 156.31 37.68 87 12325 50555 110526332
Mydriasis 140.03 37.68 62 12350 22095 110554792
Extrapyramidal disorder 127.34 37.68 63 12349 28804 110548083
Hypothermia 126.82 37.68 61 12351 26241 110550646
Hepatic cytolysis 116.10 37.68 74 12338 54979 110521908
Drug dependence 102.41 37.68 66 12346 49954 110526933
Faecaloma 101.60 37.68 44 12368 14864 110562023
Bladder dilatation 97.27 37.68 27 12385 2412 110574475
Hypotension 94.74 37.68 192 12220 523657 110053230
Asphyxia 84.13 37.68 38 12374 14177 110562710
Drug ineffective 77.82 37.68 37 12375 1520503 109056384
Akathisia 74.43 37.68 37 12375 17076 110559811
Pain 73.84 37.68 10 12402 954945 109621942
Drug reaction with eosinophilia and systemic symptoms 71.33 37.68 65 12347 82030 110494857
Hyperthermia 66.84 37.68 37 12375 21235 110555652
Intestinal obstruction 64.42 37.68 51 12361 53176 110523711
Arthralgia 63.08 37.68 7 12405 779625 109797262
Regurgitation 63.06 37.68 21 12391 3464 110573423
Sinus tachycardia 61.20 37.68 46 12366 44447 110532440
Substance abuse 60.35 37.68 29 12383 12434 110564453
Drug interaction 59.98 37.68 156 12256 500027 110076860
Cholestasis 59.82 37.68 53 12359 64465 110512422
Serotonin syndrome 59.70 37.68 51 12361 59102 110517785
Disturbance in attention 59.63 37.68 52 12360 61943 110514944
Hypercapnic coma 57.47 37.68 13 12399 502 110576385
Suicidal ideation 56.73 37.68 61 12351 93876 110483011
Pyramidal tract syndrome 56.00 37.68 14 12398 833 110576054
Bradycardia 54.88 37.68 77 12335 155440 110421447
Haemodynamic instability 53.86 37.68 33 12379 22855 110554032
Overdose 53.66 37.68 95 12317 233699 110343188
Hyponatraemia 51.97 37.68 90 12322 217563 110359324
Pneumonia 51.82 37.68 17 12395 876697 109700190
Diarrhoea 50.55 37.68 33 12379 1139472 109437415
Choking 46.70 37.68 26 12386 15084 110561803
Neuroleptic malignant syndrome 46.37 37.68 35 12377 34024 110542863
Thymus disorder 45.39 37.68 11 12401 575 110576312
Rash maculo-papular 42.71 37.68 47 12365 74175 110502712
Morbid thoughts 40.47 37.68 11 12401 908 110575979
Victim of crime 40.34 37.68 12 12400 1371 110575516
Catatonia 39.23 37.68 21 12391 11279 110565608
Lipase increased 39.09 37.68 25 12387 18647 110558240
Hepatitis acute 38.98 37.68 25 12387 18741 110558146
Pulmonary oedema 38.75 37.68 52 12360 100607 110476280
Myoclonus 38.60 37.68 31 12381 32967 110543920
Intentional product misuse 38.51 37.68 60 12352 132844 110444043

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R06AD01 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Phenothiazine derivatives
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018494 Histamine Agents
MeSH PA D000982 Antipruritics
MeSH PA D003879 Dermatologic Agents

Related Drugs by ATC class:

R06AD Phenothiazine derivatives 8 drugs
hydroxyethylpromethazineisothipendylmequitazinemethdilazineoxomemazinepromethazinethiazinamthiethylperazine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Angioedema indication 41291007 DOID:1558
General anesthesia indication 50697003
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Urticaria indication 126485001
Itching of skin indication 418363000
Allergic conjunctivitis indication 473460002 DOID:11204
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Itching Indication
Dogs Inflammation Indication
Dogs Adjunctive therapy in various cough conditions Indication
Dogs Acute or chronic bacterial infections provided the infection is controlled by appropriate antibiotic or chemotherapeutic agents Indication

🐶 Veterinary products

ProductApplicantIngredients
Temaril-P Tablets Zoetis Inc. 2
Temaril-P Spansule Capsule No. 1, Temaril-P Spansule Capsule No. 2 Zoetis Inc. 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 3.55 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST CHEMBL CHEMBL
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.90 CHEMBL

External reference:

IDSource
4019960 VUID
N0000148045 NUI
D02245 KEGG_DRUG
4330-99-8 SECONDARY_CAS_RN
4018016 VANDF
4019960 VANDF
C0041031 UMLSCUI
CHEBI:9725 CHEBI
CHEMBL829 ChEMBL_ID
5574 PUBCHEM_CID
DB01246 DRUGBANK_ID
CHEMBL3989885 ChEMBL_ID
7237 IUPHAR_LIGAND_ID
C031242 MESH_SUPPLEMENTAL_RECORD_UI
10825 RXNORM
2318 MMSL
5629 MMSL
d00788 MMSL
001535 NDDF
001536 NDDF
387471006 SNOMEDCT_US
52803004 SNOMEDCT_US
8109005 SNOMEDCT_US
D014291 MESH_DESCRIPTOR_UI
706 INN_ID
362NW1LD6Z UNII
362NW1LD6Z INXIGHT DRUGS

Pharmaceutical products:

None